We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · August 28, 2021

Inhaled Budesonide for COVID-19 in High-Risk Patients

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Inhaled Budesonide for COVID-19 in People at High Risk of Complications in the Community in the UK (PRINCIPLE): A Randomised, Controlled, Open-Label, Adaptive Platform Trial
Lancet 2021 Aug 10;[EPub Ahead of Print], LM Yu, M Bafadhel, J Dorward, G Hayward, BR Saville, O Gbinigie, O Van Hecke, E Ogburn, PH Evans, NPB Thomas, MG Patel, D Richards, N Berry, MA Detry, C Saunders, M Fitzgerald, V Harris, M Shanyinde, S de Lusignan, MI Andersson, PJ Barnes, REK Russell, DV Nicolau, S Ramakrishnan, FDR Hobbs, CC Butler

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading